Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NLG-FL7 first-line treatment study in follicular lymphoma
2023-508196-36-00Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of rituximab, lenalidomide and tafasitamab in follicular lymphoma (FL) (3 arms), sponsored by Karolinska University Hospital. Primary endpoint: EFS24. Planned start Feb 2025; status: authorised.
02
Drugs
rituximablenalidomidetafasitamab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-508196-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508196-36-00.